Research

Nuvig halts a Phase 2 trial of its lead autoimmune drug

Nuvig halted a Phase 2 trial of NVG-2089 in chronic inflammatory demyelinating polyneuropathy after deciding the program could not advance quickly enough.

Reported by 2 outlets Wednesday, October 7, 2026

Capsules scattered on a wooden table — Photo: CC0

Nuvig Therapeutics has halted one of two trials of its lead drug program, according to Fierce Biotech and Endpoints News. Fierce reported that Nuvig determined the program would not be able to advance quickly enough. Endpoints identified the stopped study as a Phase 2 trial of NVG-2089.

Endpoints said the study involved patients with chronic inflammatory demyelinating polyneuropathy. Fierce described Nuvig as Big Pharma-backed and said the halted trial was one of two trials for the company’s sole clinical asset. The reports did not say what will happen to the other trial or when the halt took effect.

Reporting on this story

Fierce Biotech Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease (opens in a new tab)

More top stories

Infectious disease

WHO and U.S. officials seek answers about Russian lab worker’s death

The cause of the lab worker’s death remains unconfirmed, and WHO assessed the risk as low for Russia and very low for Europe.

Reported by 13 outlets

Industry

Caribou halts two cancer cell therapies as it weighs strategic options

Caribou is stopping work on its two cancer cell therapy programs after failing to secure funding for planned trials.

Reported by 5 outlets

Outbreaks

Expert praises Kenya’s response to its first Ebola case

Kenyan authorities identified 28 contacts and were tracing 23 passengers and four crew members from the flight, with contacts held in isolation for 21 days.

Reported by 3 outlets

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.